壹生资讯-致敬GIST研究者丨2021年度GIST十大进展评选，快来选出你心目中的“top 10”！

您已通过HCP身份认证和信息审核

(

致敬GIST研究者丨2021年度GIST十大进展评选，快来选出你心目中的“top 10”！

2021-12-13作者：金金资讯

消化系统肿瘤原创

CSCO GIST

专栏

随着新的药物研发与治疗理念的不断更新，胃肠间质瘤（GIST）诊断与治疗模式也逐渐改变。2021年，GIST领域在临床、影像、病理、基础转化研究以及规范化诊疗方面均取得了巨大的进展，为临床诊疗提供了新的借鉴。

2022新的开始，CSCO与CMT再度携手，联合举办“胃肠间质瘤领域年度进展评选”,同时开展中国GIST DAY票选活动，由广大临床医生共同票选出中国的GIST DAY！

TOP 10

投票详情

投票说明

胃肠间质瘤领域年度进展评选

本次参与评选的20项进展包括临床研究、综述及指南。我们将采用网络读者投票的模式，选出投票最多的前十项成为2021 CSCO-CMT GIST年度十大进展，快来动动手指，为您心中的“大事件”投上宝贵一票吧！

中国GIST DAY票选

同时，为了加强临床对于GIST的重视程度，CSCO GIST专委会特别发起了设立“中国GISTDay”的倡导，哪一天是您心目中的理想“中国GISTDay”呢？也一起来参与投票吧！

投票时间

即日起至2020年12月19日00:00

投票规则

每位用户每日可以投2次，在微信端点开链接可以投1次；下载中国医学论坛报社官方APP“壹生”，成功注册可以在“壹生”APP端投票链接投1次。每次投票可选择1-10项研究。

结果公布

最终评选结果将于2022年1月15日在“第三届CSCO-再鼎临床肿瘤学新进展高峰论坛”公布，敬请期待！

{"attendFlag":0,"createTime":1639392042000,"dayEndTime":"23:59","dayStartTime":"00:00","endTime":1639843200000,"hideVotenum":true,"id":110097522,"isBindWx":0,"isOpenValidate":0,"items":[{"createTime":1639392042000,"filepathIds":"","id":2592,"imagePattern":0,"images":[],"isMultiple":1,"isNecessary":0,"maxChoicesNum":10,"minChoicesNum":1,"options":[{"createTime":1639392042000,"description":"对于局限性、高/中危险度GIST R0-R1切除后的患者，伊马替尼2年辅助治疗对比观察，中位随访9.1年，伊马替尼治疗失败生存(IFFS)有延长趋势，间接支持了SSG XVIII 研究3年伊马替尼辅助治疗明显优于1年的结果。\r\nAnn Oncol. 2021 Jan 19:S0923-7534(21)00012-0.（IF：18.274）","filepathIds":"2422250","id":10919,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/caa33445-de18-4808-bf96-9f07f0c9b35b.png","attr":"270_271"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"局限性GIST术后辅助治疗随机试验EORTC 62024的终期分析","userCount":4,"userId":2763927},{"createTime":1639392042000,"description":"该研究数据曾于2021年9月发表于Clin Cancer Res (IF 12.532).，结果提示瑞派替尼抑制了先前接受三种或三种以上TKI治疗的晚期GIST患者的广泛KIT/PDGFRA突变。\r\n在初次数据分析之后的19个月，治疗组与安慰剂组的PFS分别为6.3月(95% CI 4.6-8.1) vs 1.0月，HR=0.16，中位OS为18.2月和6.3月，HR为0.41。研究结果显示中位OS进一步获得延长。2021年ASCO更新数据显示，对于接受瑞派替尼≥四线治疗的晚期GIST患者，瑞派替尼150 mg QD治疗疾病进展后IPDE至150 mg BID可带来临床获益，中位PFS1（从随机分组到第1次疾病进展）为4.6个月，中位PFS2（从首剂瑞派替尼150mg bid到疾病进展或死亡）为3.7个月。\r\nHematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA","filepathIds":"2422260","id":10920,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/4a4f6e7b-961a-42ab-8036-08ebc52df01e.png","attr":"281_282"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"2021 ESMO，瑞派替尼四线治疗胃肠间质瘤INVICTUS研究的数据更新","userCount":23,"userId":2763927},{"createTime":1639392042000,"description":"TKI 在 SDH 缺陷型 GIST 患者中的作用存在争议，结果相互矛盾。本研究基于广泛的文献搜索，为 SDH 缺陷型 GIST 药物治疗的当前证据提供了严格概述。\r\nTher Adv Med Oncol. 2021 Jun 28;13:17588359211023278.（IF：8.168）","filepathIds":"2422253","id":10921,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/2a046e6f-9445-41cb-acf4-f52654a26f67.png","attr":"281_282"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"SDH 缺陷型 GIST 的靶向治疗","userCount":2,"userId":2763927},{"createTime":1639392042000,"description":"治疗GIST的KIT抑制剂（如伊马替尼和舒尼替尼）是非活性状态（II型）的激酶抑制剂，PLX9486是一种高选择性的与II型构象互补、活性状态（I型）的KIT抑制剂。此项1b/2a期非随机临床试验结果表明，针对同一KIT抑制剂的两个互补构象状态与临床获益有关，并具有可耐受的安全性。\r\nJAMA Oncol. 2021 Jul 8;e212086.（IF：31.773）","filepathIds":"2422254","id":10922,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/7d422190-1ba7-4dce-acc8-fdfa00ea991f.png","attr":"281_282"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"联合使用构型特异性KIT抑制剂对难治性胃肠间质瘤患者临床疗效的影响：一项 1b/2a期非随机临床试验","userCount":2,"userId":2763927},{"createTime":1639392042000,"description":"本研究为瑞派替尼治疗晚期四线GIST患者的国内桥接试验，结果显示瑞派替尼在中国人群中显示出了鼓舞人心的抗肿瘤活性：mPFS达7.2个月，ORR达18.4%，1年OS率可达65%，并且的安全性和耐受性良好。瑞派替尼在中国GIST患者中的临床获益趋势和安全性特征均与全球III期INVICTUS研究结果一致。\r\n2021年全球结缔组织肿瘤学会口头报告","filepathIds":"2422269","id":10923,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/39debb59-d1b5-44fe-95bf-8e1002d2b590.png","attr":"579_579"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"瑞派替尼四线国内桥接Ⅱ期研究","userCount":17,"userId":2763927},{"createTime":1639392042000,"description":"本项II期研究入组了至少接受过一线伊马替尼治疗的复发难治GIST患者，分析了纳武利尤单抗或纳武利尤联合伊匹木单抗在复发难治GIST患者中的疗效。研究假设RR>15%的目标未实现，但观察到有效者以及长期疾病控制。\r\nClin Cancer Res. 2021 Aug 18.（IF：12.534）","filepathIds":"2422260","id":10924,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/4a4f6e7b-961a-42ab-8036-08ebc52df01e.png","attr":"281_282"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"纳武利尤单抗单药或联合伊匹木单抗治疗晚期GIST的随机II期临床研究","userCount":1,"userId":2763927},{"createTime":1639392042000,"description":"D842V突变的GIST患者使用阿伐替尼，中位随访27.5个月，总有效率ORR、CBR分别为91%、98%，mDOR和mPFS分别为27.6个月、34.0个月，mOS未达到，且阿伐替尼在所有患者的安全性可控。阿伐替尼可作为D842V突变的GIST患者的一线治疗选择。\r\nEur J Cancer. 2021 Jan 15;145:132-142.（IF：7.275）","filepathIds":"2422252","id":10925,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/d81bb6c9-332e-41af-8c9b-9ea38ebc3c10.png","attr":"412_414"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"阿伐替尼治疗不可切除或转移性PDGFRA D842V突变的胃肠间质瘤长期随访数据","userCount":2,"userId":2763927},{"createTime":1639392042000,"description":"本大样本多中心回顾的队列研究提示，KIT外显子9突变GIST患者，伊马替尼800mg/d较400mg/d的辅助治疗剂量，没有显示出更好的生存结局。\r\nClin Cancer Res. 2021 Oct 6;clincanres.1665.2021.（IF：12.533）","filepathIds":"2422260","id":10926,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/4a4f6e7b-961a-42ab-8036-08ebc52df01e.png","attr":"281_282"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"伊马替尼辅助治疗KIT外显子9突变的GIST：一项来自欧洲的多中心回顾性研究","userCount":3,"userId":2763927},{"createTime":1639392042000,"description":"对于不可切除/转移性GIST患者，使用阿伐替尼与瑞戈非尼的疗效和安全性对比。试验未达到主要终点，阿伐替尼和瑞戈非尼的中位PFS无显著差异（4.2 vs 5.6月, 危险比1.25；95%CI, 0.99至1.57, P=0.055），两组的不良事件相似。\r\nJ Clin Oncol. 2021 Aug 3;JCO2100217.（IF：44.543）","filepathIds":"2422258","id":10927,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/3d567d12-ab3d-4919-8a80-7c2ceb669f67.png","attr":"200_201"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"阿伐替尼与瑞戈非尼治疗局部晚期不可切除或转移性胃肠间质瘤：一项随机、开放III期研究","userCount":4,"userId":2763927},{"createTime":1639392042000,"description":"此篇荟萃分析排除了肿瘤破裂的混杂效应，评估了R1切除术对GIST预后的真实影响。分析表明，R1切除并不影响GIST的生存结果。当存在阳性的显微切缘时，可能不需要重新进行手术再切除。\r\nEur J Surg Oncol. 2021 Feb 4;S0748-7983(21)00062-7.（IF：3.959）","filepathIds":"2422271","id":10928,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/1045e29a-6322-4297-b54c-bac89fd115f7.png","attr":"218_218"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"无肿瘤破裂的可切除胃肠间质瘤R1切除与肿瘤预后的相关性：一项系统回顾和荟萃分析","userCount":0,"userId":2763927},{"createTime":1639392042000,"description":"对GIST进行转移性切除的决定应在多学科的研究中做出，根据患者年龄、共病、功能状态进行个体化设置，症状，突变状态，疾病程度，切除的完整性，TKI反应，以及患者预期的目标。\r\nCurr Treat Options Oncol. 2021 Mar 20;22(5):37.（IF：3.9）","filepathIds":"2422273","id":10929,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/d7df68b4-7d02-4c0c-8f12-70e3d060aa42.png","attr":"254_255"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"转移性胃肠道间质瘤的外科治疗策略","userCount":1,"userId":2763927},{"createTime":1639392042000,"description":"对于十二指肠间质瘤（D-GIST）患者，建议应优先考虑局部切除术(LR)，因为与胰十二指肠切除术（PD）相比，LR组术后并发症发生率更低并且两组间肿瘤学预后相似。肿瘤剜除术(EN)更多用于 III/IV期肿瘤直径小于5 cm的患者，5年OS率为84.6%。\r\nAnn Surg Oncol. 2021 Apr 10.（IF：4.061）","filepathIds":"2422274","id":10930,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/49b907d4-97ec-44fe-b4c5-4ae351b3e2ba.png","attr":"279_281"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"十二指肠间质瘤局限性切除还是胰十二指肠切除？剜除术的争议：一项欧洲多中心回顾性队列研究","userCount":0,"userId":2763927},{"createTime":1639392042000,"description":"本研究共纳入2355例患有结直肠或胃GIST的患者，调整其他临床因素和倾向评分匹配（PSM）后，接受内镜治疗和手术切除患者的长期OS和癌症特异性生存（CSS）无显著差异。\r\nSurg Endosc. 2021 Oct 7.（IF：4.583）","filepathIds":"2422275","id":10931,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/4d2c29cc-b6ee-4165-930d-490c63371081.png","attr":"281_282"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"比较内镜切除和手术切除对结直肠或者胃GIST患者长期预后的对照研究","userCount":1,"userId":2763927},{"createTime":1639392042000,"description":"研究者开发了一套基于人工智能的内镜超声（EUS）诊断系统，能有效区分GIST和胃肠平滑肌瘤（GIL），提高上皮下病变（SEL）的诊断准确率。在前瞻性试验中，超声内镜诊断经组织学证实的SEL的总准确率从69.7%提高到78.8%，超声诊断GIST或GIL的准确率由73.8%提高到88.8%。\r\nEndoscopy. 2021 Apr 7.（IF：7.341）","filepathIds":"2422279","id":10932,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/8d0e600e-c7c6-4624-9e2d-359a72b76e66.png","attr":"281_282"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"内镜超声鉴别胃肠间质瘤与平滑肌瘤的人工智能系统（附视频）","userCount":1,"userId":2763927},{"createTime":1639392042000,"description":"基于早期形态学改变（EMC）的评估标准可作为预测不能切除GIST患者伊马替尼治疗疗效的敏感方法。\r\nGastric Cancer. 2021 Aug 20.（IF：7.37）","filepathIds":"2422280","id":10933,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/4fdfa46e-80bb-4e70-b056-9190f7b8c761.png","attr":"281_282"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"一种新的疗效评价标准：应用早期形态学改变判断GIST伊马替尼治疗疗效","userCount":0,"userId":2763927},{"createTime":1639392042000,"description":"该回顾性研究以出现转移的时间和总生存时间为判断预后的主要指标，排除了患者年龄、伴随疾病、确诊时间、手术及靶向治疗方案等重要参数，建立的GIST危险度评估系统，可能优于AFIP/NCCN、AJCC、改良的NIH标准等多个危险度评估系统。\r\nJ Gastroenterol. 2021 Nov;56(11):964-975.（IF：7.521）","filepathIds":"2422281","id":10934,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/de8c9d8c-8073-437e-8f5a-ddd54d7aae09.png","attr":"282_283"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"基于美国国家癌症数据库19030例病例评估的GIST风险评估评分","userCount":1,"userId":2763927},{"createTime":1639392042000,"description":"抗GPR20抗体-药物偶联物DS-6157a，在GIST异种移植模型（包括对伊马替尼，舒尼替尼和瑞戈非尼耐药的GIST模型）中表现出GPR20表达依赖性的抗肿瘤活性，其临床前药代动力学和安全性数据支持其作为潜在的新型GIST疗法。\r\nCancer Discov. 2021 Feb 12:candisc.1413.2020（IF：29.497）","filepathIds":"2422283","id":10935,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/0389672d-a2fe-48b2-bc2c-1b3c12577c9e.png","attr":"281_282"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"新药抗体-药物偶联物DS-6157a可用于选择性表达GPR20的胃肠间质瘤的识别和靶向治疗","userCount":1,"userId":2763927},{"createTime":1639392042000,"description":"对晚期GIST和早期GIST表达谱进行分析，发现CDK1在晚期GIST中高表达而在早期GIST中不表达。CDK1高表达与GIST恶性度有关，敲除CDK1会抑制细胞增殖。研究结果提示，CDK1有望成为GIST的新治疗靶点。\r\nCancer Res. 2021 Mar 16;canres.3580.2020.（IF：9.727）","filepathIds":"2422286","id":10936,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/149219f2-9fb9-4e76-96b1-874bae4c06d1.png","attr":"257_259"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"整合筛选鉴定出CDK1是晚期GIST的潜在治疗靶点","userCount":3,"userId":2763927},{"createTime":1639392042000,"description":"研究首次报告了构建患者来源琥珀酸脱氢酶突变（mSDH）GIST肿瘤模型的新方法，该模型能够应用于患者特异性肿瘤生物学研究和治疗策略的选择。研究还证明替莫唑胺对TKI靶向药物难治的mSDH GIST患者有效。\r\nClin Cancer Res. 2021 Aug 23.（IF：12.53）","filepathIds":"2422260","id":10937,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/4a4f6e7b-961a-42ab-8036-08ebc52df01e.png","attr":"281_282"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"基于患者来源的琥珀酸脱氢酶缺陷型胃肠间质瘤的模型构建及疗效预测","userCount":0,"userId":2763927},{"createTime":1639392042000,"description":"该指南由欧洲肿瘤内科学会（ESMO）联合欧洲罕见成人实体肿瘤参考网（EURACAN）以及欧洲遗传性肿瘤风险综合征参考网（GENTURIS）共同发布，指南全面介绍了基于证据和专家推荐的GIST临床诊疗实践，以期为GIST的诊断，治疗和随访提供指导建议。更新了瑞派替尼作为3种TKI治疗进展或不耐受患者的标准治疗方案。\r\nAnn Oncol. 2021 Sep 21;S0923-7534(21)04480-X.（IF：32.974）","filepathIds":"2422250","id":10938,"images":[{"filepath":"https://image.medtrib.cn/image/post/picture/2763927/caa33445-de18-4808-bf96-9f07f0c9b35b.png","attr":"270_271"}],"isRight":0,"researchId":110097522,"researchItemId":2592,"title":"胃肠间质瘤：ESMO-EURACAN-GENTURIS诊断、治疗和随访临床实践指南","userCount":5,"userId":2763927}],"researchId":110097522,"title":"2021 CSCO-CMT胃肠间质瘤年度十大进展开始投票啦！","userCount":27,"userId":2763927},{"createTime":1639392042000,"filepathIds":"","id":2593,"imagePattern":0,"images":[],"isMultiple":0,"isNecessary":0,"maxChoicesNum":1,"minChoicesNum":1,"options":[{"createTime":1639392042000,"description":"","filepathIds":"","id":10939,"images":[],"isRight":0,"researchId":110097522,"researchItemId":2593,"title":"5月20日  （取“我爱你”谐音，关爱GIST患者）","userCount":12,"userId":2763927},{"createTime":1639392042000,"description":"","filepathIds":"","id":10940,"images":[],"isRight":0,"researchId":110097522,"researchItemId":2593,"title":"7月13日（与国外GIST Day一致）","userCount":13,"userId":2763927},{"createTime":1639392042000,"description":"","filepathIds":"","id":10941,"images":[],"isRight":0,"researchId":110097522,"researchItemId":2593,"title":"8月19日（与医师节同一天，表达对医生的敬意与感谢）","userCount":0,"userId":2763927},{"createTime":1639392042000,"description":"","filepathIds":"","id":10942,"images":[],"isRight":0,"researchId":110097522,"researchItemId":2593,"title":"8月22日（中国第一部GIST诊治指南发布）","userCount":6,"userId":2763927}],"researchId":110097522,"title":"请评选出您心目中的中国GIST Day","userCount":27,"userId":2763927}],"itemsMap":{2592:{"isMultiple":1,"rightOptions":[]},2593:{"isMultiple":0,"rightOptions":[]}},"joinRange":0,"mark":2,"modifyTime":1639471451000,"researchType":0,"startTime":1639324800000,"title":"开始投票吧！","userId":2763927,"voteCount":2}

200 评论

知情同意书

致敬GIST研究者丨2021年度GIST十大进展评选，快来选出你心目中的“top 10”！

热门资讯

关于我们

中国医学论坛报微信矩阵

助力乡村振兴帮扶行动

友情链接